Oct 15, 2012
AccelDx introduces (follow link) pScreen-BNP for the diagnosis of heart failure at the In3 Medical Summit 360.
Sept 1, 2012
AccelDx receives $524,000 NIH sponsored Phase I SBIR
June 19, 2012
AccelDx's secures OFEF funding
May 23, 2012
Follow AccelDx's Investor Pitch
Feb 3, 2012
AccelDx receives Innovation Works funding
Dec 13, 2011
AccelDx signs the technology exclusive licensing agreement from Carnegie Mellon University
Oct 25, 2011
AccelDx receives funding through the Enterprise Creation Award from Carnegie Mellon to develop the Company beta prototype
|Accel Diagnostics is a medical technology company developing pScreenTM, a disposable protein test for the diagnosis, monitoring and management of a wide variety of medical conditions, including heart failure, cancer, osteoperosis, critical pregnancy, and infectious diseases. |
solution disrupts the current diagnostic market and creates new market
opportunities in the Home and Point-of-Care settings.
pScreenTM (check our demo-video) is the first
self-contained disposable blood test to measure the level of proteins
(disease biomarkers) from a single droplet of finger pricked blood, thereby enabling patients and doctors to perform diagnostic tests and access results
within 30 minutes anytime anywhere.
By providing timely, affordable, and accurate medical test
results, Accel enables physicians to manage their patients and reach disease
resolution in a timely and cost-effective manner, reducing cost and preventing hospitalizations. It also enables patients to monitor and effectively manage the
progression of their chronic diseases in the comfort of their home. AccelDx's platform technology leverages a patent-protected magnetic
microfluidic system developed at Carnegie Mellon University.